BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 25448465)

  • 21. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
    Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
    Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.
    Wang Q; Chen Q; Zhang X; Lu XL; Du Q; Zhu T; Zhang GY; Wang DS; Fan QM
    World J Gastroenterol; 2019 Sep; 25(36):5515-5529. PubMed ID: 31576097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ; Han KH; Kim DY
    Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of serum PIVKA-II and MIF as diagnostic markers for HCV/HBV induced hepatocellular carcinoma.
    Kamel MM; Saad MF; Mahmoud AA; Edries AA; Abdel-Moneim AS
    Microb Pathog; 2014 Dec; 77():31-5. PubMed ID: 25448465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serological markers of liver cancer.
    Yuen MF; Lai CL
    Best Pract Res Clin Gastroenterol; 2005 Feb; 19(1):91-9. PubMed ID: 15757806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tumor markers for hepatocellular carcinoma].
    Tateishi R; Enooku K; Shiina S; Koike K
    Nihon Rinsho; 2012 May; 70(5):821-7. PubMed ID: 22620007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.
    Bertino G; Neri S; Bruno CM; Ardiri AM; Calvagno GS; Malaguarnera M; Toro A; Malaguarnera M; Clementi S; Bertino N; Di Carlo I
    Minerva Med; 2011 Oct; 102(5):363-71. PubMed ID: 22193346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [PIVKA-II high-sensitivity PIVKA-II].
    Fujiyama S
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():349-55. PubMed ID: 11761970
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.
    Bertino G; Ardiri AM; Calvagno GS; Bertino N; Boemi PM
    Drug News Perspect; 2010 Oct; 23(8):498-508. PubMed ID: 21031166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis].
    Aoyagi Y; Yanagi M; Asakura H
    Nihon Naika Gakkai Zasshi; 1995 Dec; 84(12):2003-7. PubMed ID: 8586921
    [No Abstract]   [Full Text] [Related]  

  • 33. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.
    Kim DY; Toan BN; Tan CK; Hasan I; Setiawan L; Yu ML; Izumi N; Huyen NN; Chow PK; Mohamed R; Chan SL; Tanwandee T; Lee TY; Hai TTN; Yang T; Lee WC; Chan HLY
    Clin Mol Hepatol; 2023 Apr; 29(2):277-292. PubMed ID: 36710606
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.